Clinical efficacy of recombinant human endostatin injection combined with chemotherapy in the treatment of ;patients with advanced gastric cancer and its influence on the quality of life
10.3760/cma.j.issn.1008-6706.2016.19.001
- VernacularTitle:重组人血管内皮抑制素注射液联合化疗治疗晚期胃癌合并恶性腹水的临床疗效及对患者生活质量的影响
- Author:
Jianying JIN
;
Qun GUO
;
Zhengrong WANG
;
Jingjing XIE
;
Dan JIN
- Publication Type:Journal Article
- Keywords:
Recombinant human endostatin injection;
Chemotherapy;
Stomach neoplasms;
Malignant ascites;
Curative effect;
Quality of life
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(19):2881-2884,2885
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical curative effect of recombinant human endostatin injection combined with chemotherapy in the treatment of patients with advanced gastric cancer and malignant ascites,and its influence on the quality of life.Methods 62 patients with advanced gastric cancer from July 2012 to July 2015,were randomly divided into observation group (31 cases)and control group (31 cases).The control group was treated with FOLFOX6 chemotherapy,the observation group was given recombinant human endostatin injection on the basis of the treatment of the control group.The two groups were treated for 3 weeks.The curative effect,QOL score,Karnofsky score,the change of serum CEA and CA19 -9 levels and drug adverse reaction incidence before and after treatment were compared in the two groups.Results The RR of the observation group was higher than that of the control group (54.84 vs 29.03%,χ2 =4.239 3,P <0.05).The QOL score and Karnofsky score in the two groups were increased after treatment (P <0.05).The QOL score and Karnofsky score after treatment in the observation group were higher than the control group(t =6.512 7,5.669 0,all P <0.05).The serum CEA and CA19 -9 levels of the two groups decreased significantly after treatment (P <0.05).The serum CEA and CA19 -9 levels of the observation group were lower than the control group after treatment (t =5.276 0,6.310 8,all P <0.05).The leukopenia,thrombocytopenia, peripheral neurotoxicity,decreased hemoglobin,diarrhea,nausea and vomiting adverse reaction rate of the two groups had no significant differences (P >0.05).Conclusion The clinical efficacy of recombinant human endostatin injec-tion combined with malignant ascites in the treatment of patients with advanced gastric carcinoma is significant,and can significantly improve the quality of life of patients,has the important research value.
